The Jackson Laboratory

JAX Symposium

In Vivo Strategies to Improve the Design of Therapeutic Antibodies and Albumin Fusion Protein Drugs

Learn how the JAX platform of mouse models expressing human neonatal Fc receptor (hFcRn) can be exploited to acquire pharmacokinetic and pharmacodynamic data for Fc-containing molecules that models human or nonhuman primate performance in a fast and cost-effective manner. This free event features talks by two leaders in the field: Greg Christianson and Dr. Jan Terje Andersen.



Please fill out the form to register. Upon submission a confirmation will be sent to the email address provided.

Symposium Details

Date & Location

Friday, September 20th
Tamburlaine
27-29 Station Rd
Cambridge, UK CB1 2FB

Agenda:

09:30 - 10:30:   Registration and networking over coffee
10:30 - 10:45:   Welcome and introduction to JAX
10:45 - 11:30:   Greg Christianson: JAX® hFcRn Mice: The Fast-Track to Clinically Relevant PK/PD Data for both Antibody and Albumin Therapeutics
11:30 - 12:15:   Dr. Jan Terje Andersen: Design of Biologics for Better Performance
12:15: Lunch

Symposium Speakers

Greg Christianson
Study Director, In Vivo Pharmacology
The Jackson Laboratory, Bar Harbor, ME
Presenting: JAX® hFcRn Mice: The Fast-Track to Clinically Relevant PK/PD Data for both Antibody and Albumin Therapeutics

The development of mice humanized for FcRn expression has provided a superior method for acquiring pharmacokinetic and pharmacodynamic data that exceed expectations in their ability to model human or nonhuman primate performance. I plan to present a general overview of FcRn biology, and review PK data from all our hFcRn models to provide a flavor of what’s available.

Dr. Jan Terje Andersen
Research Group Leader
Oslo University Hospital and Unversity of Oslo, Norway
Presenting: Design of Biologics for Better Performance

The half-life of the two most abundant proteins in blood, IgG and serum albumin, is roughly 3 weeks. This has made IgG the natural choice for design of antibody therapeutics, while albumin is increasingly used as a fusion partner. Remarkably, the half-life of these unrelated proteins is prolonged by a common receptor, FcRn. I will present strategies for design of novel albumin and antibody molecules with improved functions that may translate into new biologics.


IMPORTANT FEATURES

Bootstrap Grid

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Responsive Design

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Detailed Documentation

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Free Support

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.